Biotech Values

[DewDiligence]

EASL Post-Mortem

Biotech analyst, Mark Schoenebaum, surveyed approximately 100 buy-side analysts, asking them which company was the biggest winner at EASL. The responses were as follows:

VRUS 68%
BMY 9%
INHX 6%
ACHN 4%
GILD 4%
Medivir 4%
VRTX 4%
*JNJ 2%
All other: 0%

The definition of being a winner was not explicitly stated, but the respondents presumably thought it was a measure of how much a given company exceeded expectations. (That’s why VRTX, for instance, had a low vote in the survey—the most consequential data VRTX released at EASL were the IL28B stratifications in #msg-61716397—while INHX had a relatively high vote despite releasing also-ran data.)

Sorry, I do not have a link for this survey info.

*JNJ is partnered with both VRTX and Medivir.